4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological...

Area of Science:

• Medicinal Chemistry
• Oncology
• Biochemistry

Background:

• Estrogen receptor-positive breast cancer relies on estrogen for growth, making aromatase inhibitors a primary treatment.
• Current aromatase inhibitors face challenges due to acquired resistance and potential toxicities.
• Developing novel inhibitors is crucial to overcome resistance and improve patient outcomes.

Purpose of the Study:

• To design and synthesize novel triazole-based compounds as potential fourth-generation aromatase inhibitors.
• To explore dual binding mechanisms at both the active site and access channel of aromatase (CYP19A1).
• To establish structure-activity relationships and assess the safety profile of new inhibitors.

Main Methods:

• Design of novel triazole-based inhibitors based on a parent compound and CYP19A1 crystal structure.
• Synthesis of modified compounds with long-chain substituents.
• Evaluation of aromatase inhibition (IC50 values) and molecular dynamics studies.
• Toxicity assays and CYP selectivity profiling.

Main Results:

• Compound 13h demonstrated high potency with an IC50 value in the low picomolar range (0.09 nM).
• Molecular dynamics studies confirmed a favorable dual binding mode, elucidating structure-activity relationships.
• Initial toxicity and selectivity studies indicated a potentially favorable safety profile for some compounds.

Conclusions:

• Novel triazole-based compounds exhibit potent aromatase inhibition and a dual binding mechanism.
• These findings provide a strong foundation for the development of fourth-generation nonsteroidal aromatase inhibitors.
• The new inhibitors may offer a strategy to overcome resistance and minimize adverse effects in breast cancer treatment.